Low levels of plasma agmatine in the metabolic syndrome

Metabolic Syndrome and Related Disorders

Volumn 8, Issue 1, 2010, Pages 21-24

  Jo, Inho ^a   Han, Changsu ^b   Ahn Jo, Sangmee ^c   Seo, Ji Ah ^b   Park, Moon Ho ^b   Kim, Nan Hee ^b  

^a Ewha Womans University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Korea National Institute of Health   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGMATINE; ARGININE; BIOLOGICAL MARKER;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ASIAN; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; EDUCATION PROGRAM; FEMALE; GERIATRICS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; AGMATINE; ARGININE; BIOLOGICAL MARKERS; BIOPHYSICS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; HUMANS; KOREA; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, BIOLOGICAL; ODDS RATIO; REGRESSION ANALYSIS;

EID: 77649106290     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2009.0032     Document Type: Article

References (25)

1. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
2. Feng Y, Halaris AE, Piletz JE. Determination of agmatine in brain and plasma using high-performance liquid chromatography with fl uorescence detection. J Chromatogr B Biomed Sci Appl 1997;691:277-286.
3. Raasch W, Regunathan S, Li G, Reis DJ. Agmatine is widely and unequally distributed in rat organs. Ann NY Acad Sci 1995;763:330-334.
4. Haulica I, Bild W, Iliescu R, Georgescu R, Frunza F. Preliminary research on possible relationship of NO with agmatine at the vascular level. Rom J Physiol 1999;36:67-79.
5. Ishikawa T, Misonou T, Ikeno M, Sato K, Sakamaki T. N omega- hydroxyagmatine: a novel substance causing endothelium- dependent vasorelaxation. Biochem Biophys Res Commun 1995;214:145-151.
6. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761.
7. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991;10:339-352.
8. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
9. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama 2002;288:2709-2716.
10. Han C, Jo SA, Kim NH, Jo I, Park MH. Study design and methods of the Ansan Geriatric Study (AGE study). BMC Neurol 2009;9:10.
11. Kim J, Park MH, Kim E, Han C, Jo SA, Jo I. Plasma homocysteine is associated with the risk of mild cognitive impairment in an elderly Korean population. J Nutr 2007;137:2093-2097.
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001;285:2486-2497.
13. Euler DE. Is there a therapeutic role for Agmatine? Anadolu Kardiyol Derg 2006;6:39-40.
14. Reis DJ, Regunathan S. Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann NY Acad Sci 1999;881:65-80.
15. Santos WC, Hernandez-Guijo JM, Ruiz-Nuno A, Olivares R, Jurkiewicz A, Gandia L, et al. Blockade by agmatine of catecholamine release from chromaffi n cells is unrelated to imidazoline receptors. Eur J Pharmacol 2001;417:99-109.
16. Shepherd RM, Hashmi MN, Kane C, Squires PE, Dunne MJ. Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: Implications for stimulus-response coupling of insulin release. Br J Pharmacol 1996;119:911-916.
17. Schwartz D, Peterson OW, Mendonca M, Satriano J, Lortie M, Blantz RC. Agmatine affects glomerular fi ltration via a nitric oxide synthase-dependent mechanism. Am J Physiol 1997;272:F597-F601.
18. Szabo B, Urban R, Limberger N, Starke K. Cardiovascular effects of agmatine, a "clonidine-displacing substance," in conscious rabbits. Naunyn Schmiedebergs Arch Pharmacol 1995;351:268-273.
19. Li Q, Yin JX, He RR. Effect of agmatine on L-type calcium current in rat ventricular myocytes. Acta Pharmacol Sin 2002;23:219-224.
20. Wang G, Gorbatyuk OS, Dayanithi G, Ouyang W, Wang J, Milner TA, et al. Evidence for endogenous agmatine in hypothalamo- neurohypophysial tract and its modulation on vasopressin release and Ca2+ channels. Brain Res 2002;932:25-36.
21. Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996;316(Pt 1):247-249.
22. Satriano J, Schwartz D, Ishizuka S, Lortie MJ, Thomson SC, Gabbai F, et al. Suppression of inducible nitric oxide generation by agmatine aldehyde: Benefi cial effects in sepsis. J Cell Physiol 2001;188:313-320.
23. Kim JH, Yenari MA, Giffard RG, Cho SW, Park KA, Lee JE. Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. Exp Neurol 2004;189:122-130.
24. Greenberg S, George J, Wollman Y, Shapira I, Laniado S, Keren G. The effect of agmatine administration on ischemic-reperfused isolated rat heart. J Cardiovasc Pharmacol Ther 2001;6:37-45.
25. Myung CS, Blankenship JW, Meerdink DJ. A mechanism of vasodilatory action of polyamines and acetylpolyamines: possible involvement of their Ca2+ antagonistic properties. J Pharm Pharmacol 2000;52:695-707.